Palvella Therapeutics (PVLA) to Release Earnings on Thursday

05 May 2026, 16:48 by Jessica Moore · The Cerbat Gem

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Palvella Therapeutics to post earnings of ($0.90) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13). On average, analysts expect Palvella Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Palvella Therapeutics Price Performance

PVLA stock traded up $1.86 on Tuesday, reaching $129.47. The company’s stock had a trading volume of 212,303 shares, compared to its average volume of 286,958. Palvella Therapeutics has a 52 week low of $20.20 and a 52 week high of $151.18. The company has a market capitalization of $1.85 billion, a P/E ratio of -34.90 and a beta of -0.13. The firm has a fifty day moving average of $124.68 and a two-hundred day moving average of $101.37.

Insider Activity

In other news, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $125.00 per share, with a total value of $500,000.00. Following the purchase, the director directly owned 187,171 shares in the company, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Large investors have recently added to or reduced their stakes in the company. Group One Trading LLC raised its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at $36,000. The Manufacturers Life Insurance Company acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $238,000. Virtus Investment Advisers LLC acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $282,000. Finally, JPMorgan Chase & Co. raised its stake in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. 40.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on PVLA. BTIG Research increased their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research report on Tuesday, February 24th. Mizuho upped their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Truist Financial set a $210.00 target price on Palvella Therapeutics in a research report on Tuesday, February 24th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $198.07.

View Our Latest Report on PVLA

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.